Breast cancer drug halves return risk
9th Dec 2005, 15:42 GMT
The breast cancer drug Herceptin could halve the risk of early stage aggressive cancer returning, according to the latest international study. Doctors said the results confirmed the 'outstanding benefit' of Herceptin, which is not currently approved for early stages of the disease in the UK
Breast cancer drug halves return risk related news:
- Breast cancer drug 'halves risk' — the Mail online | Health news
- Drug for cancer is successful — Scotsman.com News - Breast cancer
- Low-Fat Diet May Prevent Breast Cancer Recurrence — Breast Cancer Chronicles
- Herceptin proving to be a wonder drug — The Cardio Blog
- Breast cancer survivors face more risks — HEALTH
- Breast cancer increases risk of a second cancer — Health News
- New breast cancer drug prevents future cancer growth — The Cancer Blog
- Women With Breast Cancer Face Increased Risk Of Developing A Second Cancer — ScienceDaily Headlines: Health & Medicine
- Breast cancer drug extension — Scotsman.com News - Breast cancer
- Breast cancer drug cuts death risk — the Mail online | Health
Latest news from the Mail online | Health:
- Designer twins are born healthy after screened for cystic fibrosis
- NICE refuse to fund life-prolonging cancer drug available in Scotland
- Dentist shortage leads man to superglue own tooth
- NICE refuses to fund life-prolonging cancer drug available in Scotland
- I was frozen to improve my health
- Why do I have dark circles under my eyes?
- Why smokers must have equal rights to health care
- Warning: Nurses at work
- I thought only women got osteoporosis - until my back exploded on the dance floor
- How you can snuff out the snuffles